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Experimental:  
SEC-ICP-MS  
An Agilent 1100 HPLC (Agilent Technologies, Waldbronn, Germany) fitted with a BioSeP-
SEC-S 2000 guard column 30 x 4.6 mm, (Phenomenex, Taastrup, Denmark) and a BioSep 
2000-S size exclusion column, 5 µm particles, 300 x 4.6mm (Phenomenex, Taastrup, 
Denmark). The mobile phase was 50 mM NH4HCO3, pH 7.8 with a flow of 350 µL min
-1
 and 
10 µL sample diluted with mobile phase was injected using the autosampler from the HPLC 
system. The Pt signal was recorded using an ICP-MS, Elan 6000 (Perkin Elmer, Concord, 
ON, Canada).The spray chamber was a PC
3
 cyclonic spray chamber (Elemental Scientific Inc, 
Omaha, NE, USA) fitted with a Mira Mist parallel nebulizer (Burgener Research, 
Mississauga, ON, Canada). The nebulizer gas was adjusted externally to a flow of around 1 L 
min
-1
. The ICP-MS settings were: Lens voltage: 7V, RF power: 900W, dwell time: 100 ms 
and the Pt signals were recorded at m/z 195 and 196. Data were processed using WSearch32 
V1.6.2005 (a freely available mass spectral data reduction program).   
 
LC-MS/MS (MS
E
 and data search using PLGS and Excel)  
Low and elevated energy MS spectra were both acquired from m/z 50 to 1990 for 0.48 s each 
with a 0.02-s interscan delay. In low energy MS mode, data were collected at a constant 
collision energy of 4 eV. In elevated energy MS mode, the collision energy was ramped from 
15 to 40 eV during each 0.48 s data collection cycle with one complete cycle of low and 
elevated energy data acquired every 1.0 s. The radio frequency applied to the quadrupole 
mass analyzer was adjusted such that ions from m/z 300 to 1990 were efficiently transmitted, 
ensuring that any ions less than m/z 300 observed in the LC-MS data only arose from 
dissociations in the collision cell. DIA LC-MS
E
 raw data files were processed using 
ProteinLynx GlobalServer (PLGS) version 2.4 (Waters Corporation) and subsequent database 
searching was performed using the Ion Accounting algorithm
1
, embedded in PLGS, searching 
the supplied human SwissProt database and as well a specific database with the porcine 
insulin A chain and B chain included. The search tolerances were set to automatic (typically 
10 ppm for precursor and 25 ppm for product ions), with oxidation of methionine, and 
deamidation of asparagine and glutamine set as variable modifications. Furthermore, to search 
for peptides with oxaliplatin, masses corresponding to attachment of Pt(dach) and 
Pt(dach)+OH (307.07 Da and 324.07 Da) were included as variable modifications  and also 
masses 306.07 Da and 323.07 Da to allow for loss of a proton upon binding to insulin. For 
certain samples acrylamide and carbamidomethyl modification for cysteine residues were set 
as fixed modifications. Other settings included, minimum number of peptide matches (3), 
minimum number of product ion matches per peptide (3), minimum number of product ion 
matches per protein (5), maximum number of missed V8 cleavage sites (2), and maximum 
false positive rate (5%). PLGS was configured to also output results as csv-files for further 
analysis in Excel (Microsoft Corporation, Redmond, WA).  
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Fig. S1: MALDI-TOF-MS spectrum of intact insulin-oxaliplatin analyzed by MALDI-ToF-MS (Voyager-DE)  
 
 
Fig. S2: SEC-ICP-MS chromatogram of reduced insulin-oxaliplatin complex as well as free oxaliplatin 
 
 
Fig. S3: The deconvoluted nESI-Q-ToF- mass spectrum of  reduced insulin-oxaliplatin. A denotes the A chain and B denotes the B chain of insulin  
 
 
Fig. S4: MALDI-ToF MS/MS spectrum of a: B1+Pt(dach) at m/z 1789.71, b: A1+Pt(dach) at m/z 724.26  
 
 
Fig. S5: MALDI-ToF-ToF-MS/MS spectrum of B1+Pt(dach)+acrylamide at m/z 1860.7  
 
 
Fig. S6: MALDI-ToF-ToF- MS/MS spectrum of B1+Pt(dach) at m/z 1789.71  
 
 
Table S1: Overview of peptides formed after digestion only, and after both digestion and reduction of insulin-oxaliplatin identified with MALDI-
ToF-ToF-MS/MS.  The bottom part shows the peptides with Pt(dach) attached after incubation of digested only, and both digested and reduced 
peptides with oxaliplatin for 2 hours at 37 °C  
 
 
